Tolerability · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in tolerability compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · people with sickle cell disease
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin leads to higher significant improvement in disability within 6 weeks compared with placebo (high certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Quit at longest · smoking cessation in hospitalised patients
Pharmacotherapy plus counselling leads to higher quit at longest compared with no pharmacotherapy or placebo plus counselling (high certainty).
3 findings from 1 review
RR 1.33 [1.05, 1.67]
8 studies · 3838 participants
High
RR 1.11 [0.86, 1.43]
4 studies · 872 participants
Low
RR 1.29 [0.96, 1.75]
4 studies · 829 participants
Moderate
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
Time to next pulmonary exacerbation · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events: number of mild treatment‐related adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Hospital admissions · adults and children with cystic fibrosis
1 finding from 1 review
New acquisition of CF pathogens: PA · adults and children with cystic fibrosis
1 finding from 1 review
Need for additional antibiotics: participants needing extra IV antibiotics · adults and children with cystic fibrosis
1 finding from 1 review
QoL · adults and children with cystic fibrosis
1 finding from 1 review
OutcomesTime frame of absolute effects · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment responsea · children and young people with JIA
Methotrexate may leads to higher treatment responsea(up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
Sustained clinically inactive diseasec · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Function · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain on motion · children and young people with JIA
1 finding from 1 review
Global well‐being: rated by participants · children and young people with JIA
Methotrexate showed no clear difference in participant global assessment of well‐being(up to 6 months) compared with placebo (low certainty).
1 finding from 1 review